HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Cell Lines and Primary Monocyte Cultures
2.2. Metabolic Activity
2.3. Apoptosis in Cocultures of Monocytes and Mesothelioma Cells
2.4. Live Cell Imaging
2.5. Confocal Microscopy
2.6. H3K27me3 and Kac Immunofluorescence
2.7. RNA Sequencing and Bioinformatic Analysis
2.8. Statistics
3. Results
3.1. HDAC Inhibition Promotes THP-1 Cytotoxicity towards MPM Cells
3.2. Blood-Derived Monocytes Exert a Direct Cytotoxic Activity against MPM Cells
3.3. VPA Positively Modulates the Cytotoxic Activity of Blood-Derived Monocytes against MPM Cells
3.4. VPA Primarily Affects Binding and Downregulates M2 Markers
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Alpert, N.; van Gerwen, M.; Taioli, E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl. Lung Cancer Res. 2020, 9, S28–S38. [Google Scholar] [CrossRef] [PubMed]
- Brcic, L.; Kern, I. Clinical significance of histologic subtyping of malignant pleural mesothelioma. Transl. Lung Cancer Res. 2020, 9, 924–933. [Google Scholar] [CrossRef] [PubMed]
- Scherpereel, A.; Opitz, I.; Berghmans, T.; Psallidas, I.; Glatzer, M.; Rigau, D.; Astoul, P.; Bölükbas, S.; Boyd, J.; Coolen, J.; et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur. Respir. J. 2020, 55, 1900953. [Google Scholar] [CrossRef] [PubMed]
- Janes, S.M.; Alrifai, D.; Fennell, D.A. Perspectives on the Treatment of Malignant Pleural Mesothelioma. N. Engl. J. Med. 2021, 385, 1207–1218. [Google Scholar] [CrossRef] [PubMed]
- Vogelzang, N.J.; Rusthoven, J.J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffie, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C.; et al. Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. J. Clin. Oncol. 2003, 21, 2636–2644. [Google Scholar] [CrossRef]
- Petrelli, F.; Ardito, R.; Conti, B.; Coinu, A.; Cabiddu, M.; Ghilardi, M.; Borgonovo, K.; Barni, S.; Ghidini, A. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. Respir. Med. 2018, 141, 72–80. [Google Scholar] [CrossRef]
- Baas, P.; Scherpereel, A.; Nowak, A.K.; Fujimoto, N.; Peters, S.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Jahan, T.; Antonia, S.; et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet 2021, 397, 375–386. [Google Scholar] [CrossRef]
- Salas-Benito, D.; Pérez-Gracia, J.L.; Ponz-Sarvisé, M.; Rodriguez-Ruiz, M.E.; Martínez-Forero, I.; Castañón, E.; López-Picazo, J.M.; Sanmamed, M.F.; Melero, I. Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discov. 2021, 11, 1353–1367. [Google Scholar] [CrossRef]
- Brossel, H.; Fontaine, A.; Hoyos, C.; Jamakhani, M.; Willems, M.; Hamaidia, M.; Willems, L. Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma. Cancers 2021, 13, 3211. [Google Scholar] [CrossRef]
- Cersosimo, F.; Barbarino, M.; Lonardi, S.; Vermi, W.; Giordano, A.; Bellan, C.; Giurisato, E. Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms. Cancers 2021, 13, 5664. [Google Scholar] [CrossRef]
- Hegmans, J.P.J.J.; Hemmes, A.; Hammad, H.; Boon, L.; Hoogsteden, H.C.; Lambrecht, B.N. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur. Respir. J. 2006, 27, 1086–1095. [Google Scholar] [CrossRef]
- Rippo, M.; Villanova, F.; Procopio, A. Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies. Curr. Med. Chem. 2008, 15, 631–641. [Google Scholar] [CrossRef]
- Cornelissen, R.; Lievense, L.A.; Robertus, J.L.; Hendriks, R.W.; Hoogsteden, H.C.; Hegmans, J.P.; Aerts, J.G. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. Lung Cancer 2015, 88, 332–337. [Google Scholar] [CrossRef]
- Lievense, L.A.; Cornelissen, R.; Bezemer, K.; Aerts, J.G. Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression. J. Thorac. Oncol. 2016, 11, 1755–1764. [Google Scholar] [CrossRef] [Green Version]
- Minnema-Luiting, J.; Vroman, H.; Aerts, J.; Cornelissen, R. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. Int. J. Mol. Sci. 2018, 19, 1041. [Google Scholar] [CrossRef] [Green Version]
- Grosso, S.; Marini, A.; Gyuraszova, K.; Voorde, J.; Vande Sfakianos, A.; Garland, G.D.; Tenor, A.R.; Mordue, R.; Chernova, T.; Morone, N.; et al. The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nat. Commun. 2021, 12, 4920. [Google Scholar] [CrossRef]
- Burt, B.M.; Rodig, S.J.; Tilleman, T.R.; Elbardissi, A.W.; Bueno, R.; Sugarbaker, D.J. Circulating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma. Cancer 2011, 117, 5234–5244. [Google Scholar] [CrossRef]
- Tanrikulu, A.C.; Abakay, A.; Komek, H.; Abakay, O. Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma. Environ. Health Prev. Med. 2016, 21, 304–311. [Google Scholar] [CrossRef] [Green Version]
- Cantini, L.; Belderbos, R.; Gooijer, C.; Dumoulin, D.; Cornelissen, R.; Baart, S.; Burgers, J.; Baas, P.; Aerts, J. Nivolumab in pre-treated malignant pleural mesothelioma: Real-world data from the Dutch expanded access program. Transl. Lung Cancer Res. 2020, 9, 1169–1179. [Google Scholar] [CrossRef]
- Yamagishi, T.; Fujimoto, N.; Nishi, H.; Miyamoto, Y. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer 2015, 90, 111–117. [Google Scholar] [CrossRef]
- Belge, K.-U.; Dayyani, F.; Horelt, A.; Siedlar, M.; Frankenberger, M.; Frankenberger, B.; Espevik, T.; Ziegler-Heitbrock, L. The Proinflammatory CD14+CD16+DR++Monocytes Are a Major Source of TNF. J. Immunol. 2002, 168, 3536–3542. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, K.L.; Tai, J.J.Y.; Wong, W.C.; Han, H.; Sem, X.; Yeap, W.H.; Kourilsky, P.; Wong, S.C. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011, 118, e16–e31. [Google Scholar] [CrossRef] [Green Version]
- Cros, J.; Cagnard, N.; Woollard, K.; Patey, N.; Zhang, S.Y.; Senechal, B.; Puel, A.; Biswas, S.K.; Moshous, D.; Picard, C.; et al. Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors. Immunity 2010, 33, 375–386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yeap, W.H.; Wong, K.L.; Shimasaki, N.; Teo, E.C.Y.; Quek, J.K.S.; Yong, H.X.; Diong, C.P.; Bertoletti, A.; Linn, Y.C.; Wong, S.C. CD16 is indispensable for antibody dependent cellular cytotoxicity by human monocytes. Sci. Rep. 2016, 6, 34310. [Google Scholar] [CrossRef]
- Hamaidia, M.; Gazon, H.; Hoyos, C.; Hoffmann, G.B.; Louis, R.; Duysinx, B.; Willems, L. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism. JCI Insight 2019, 4, e128474. [Google Scholar] [CrossRef] [PubMed]
- Holze, C.; Michaudel, C.; Mackowiak, C.; Haas, D.A.; Benda, C.; Pennemann, F.L.; Schnepf, D.; Wettmarshausen, J.; Braun, M.; Leung, D.W.; et al. Oxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway. Nat. Immunol. 2018, 19, 130–140. [Google Scholar] [CrossRef] [PubMed]
- Mola, S.; Pinton, G.; Erreni, M.; Corazzari, M.; Andrea MDe Grolla, A.A.; Martini, V.; Moro, L.; Porta, C. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids. Int. J. Mol. Sci. 2021, 22, 4391. [Google Scholar] [CrossRef] [PubMed]
- Chéné, A.-L.; Almeida, S.; Blondy, T.; Tabiasca, J.; Deshayes, S.; Fonteneau, J.-F.; Cellerin, L.; Delneste, Y.; Gregoire, M.; Blanquart, C. Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages. J. Thorac. Oncol. 2016, 11, 1765–1773. [Google Scholar] [CrossRef] [Green Version]
- Lund, M.E.; To, J.; O’Brien, B.A.; Donnelly, S. The choice of phorbol 12-myristate 13-acetate differentiation protocol influences the response of THP-1 macrophages to a pro-inflammatory stimulus. J. Immunol. Methods 2016, 430, 64–70. [Google Scholar] [CrossRef]
- Richter, E.; Ventz, K.; Harms, M.; Mostertz, J.; Hochgräfe, F. Induction of Macrophage Function in Human THP-1 Cells Is Associated with Rewiring of MAPK signaling and Activation of MAP3K7 (TAK1) Protein Kinase. Front. Cell Dev. Biol. 2016, 4. [Google Scholar] [CrossRef] [Green Version]
- Piccinini, F.; Kiss, A.; Horvath, P. CellTracker (not only) for dummies. Bioinformatics 2016, 32, 955–957. [Google Scholar] [CrossRef]
- Galluzzi, L.; Bravo-San Pedro, J.M.; Vitale, I.; Aaronson, S.A.; Abrams, J.M.; Adam, D.; Alnemri, E.S.; Altucci, L.; Andrews, D.; Annicchiarico-Petruzzelli, M.; et al. Essential versus accessory aspects of cell death: Recommendations of the NCCD 2015. Cell Death Differ. 2015, 22, 58–73. [Google Scholar] [CrossRef] [Green Version]
- Scherpereel, A.; Berghmans, T.; Lafitte, J.J.; Colinet, B.; Richez, M.; Bonduelle, Y.; Meert, A.P.; Dhalluin, X.; Leclercq, N.; Paesmans, M.; et al. Valproate-doxorubicin: Promising therapy for progressing mesothelioma. A phase II study. Eur. Respir. J. 2011, 37, 129–135. [Google Scholar] [CrossRef] [Green Version]
- Forrester, M.A.; Wassall, H.J.; Hall, L.S.; Cao, H.; Wilson, H.M.; Barker, R.N.; Vickers, M.A. Similarities and differences in surface receptor expression by THP-1 monocytes and differentiated macrophages polarized using seven different conditioning regimens. Cell. Immunol. 2018, 332, 58–76. [Google Scholar] [CrossRef] [Green Version]
- Noguchi, S.; Eitoku, M.; Moriya, S.; Kondo, S.; Kiyosawa, H.; Watanabe, T.; Suganuma, N. Regulation of Gene Expression by Sodium Valproate in Epithelial-to-Mesenchymal Transition. Lung 2015, 193, 691–700. [Google Scholar] [CrossRef]
- Felisbino, M.B.; Ziemann, M.; Khurana, I.; Okabe, J.; Al-Hasani, K.; Maxwell, S.; Harikrishnan, K.N.; de Oliveira, C.B.M.; Mello, M.L.S.; El-Osta, A. Valproic acid influences the expression of genes implicated with hyperglycaemia-induced complement and coagulation pathways. Sci. Rep. 2021, 11, 2163. [Google Scholar] [CrossRef]
- Yunna, C.; Mengru, H.; Lei, W.; Weidong, C. Macrophage M1/M2 polarization. Eur. J. Pharmacol. 2020, 877, 173090. [Google Scholar] [CrossRef]
- Zanatta, G.; Sula, A.; Miles, A.J.; Ng, L.C.T.; Torella, R.; Pryde, D.C.; DeCaen, P.G.; Wallace, B.A. Valproic acid interactions with the NavMs voltage-gated sodium channel. Proc. Natl. Acad. Sci. USA 2019, 116, 26549–26554. [Google Scholar] [CrossRef]
- Razzaghi, N.; Fernandez-Gonzalez, P.; Mas-Sanchez, A.; Vila-Julià, G.; Perez, J.J.; Garriga, P. Effect of Sodium Valproate on the Conformational Stability of the Visual G Protein-Coupled Receptor Rhodopsin. Molecules 2021, 26, 3032. [Google Scholar] [CrossRef]
- Liu, J.; Wang, Y.; Birnbaum, M.J.; Stoffers, D.A. Three-amino-acid-loop-extension homeodomain factor Meis3 regulates cell survival via PDK1. Proc. Natl. Acad. Sci. USA 2010, 107, 20494–20499. [Google Scholar] [CrossRef] [Green Version]
- Chancellor, A.; Gadola, S.D.; Mansour, S. The versatility of the CD1 lipid antigen presentation pathway. Immunology 2018, 154, 196–203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Flaherty, D.K. Antigen-Presenting Molecules. In Immunology for Pharmacy; Flaherty, D.K., Ed.; Mosby: Maryland Heights, MO, USA, 2012; pp. 31–36. [Google Scholar] [CrossRef]
- Bode, K.A.; Dalpke, A.H. HDAC inhibitors block innate immunity. Blood 2011, 117, 1102–1103. [Google Scholar] [CrossRef] [PubMed]
- Roger, T.; Lugrin, J.; Le Roy, D.; Goy, G.; Mombelli, M.; Koessler, T.; Ding, X.C.; Chanson, A.L.; Reymond, M.K.; Miconnet, I.; et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011, 117, 1205–1217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, C.; Li, A.; Leng, Y.; Li, Y.; Kang, J. Histone Deacetylase Inhibition by Sodium Valproate Regulates Polarization of Macrophage Subsets. DNA Cell Biol. 2012, 31, 592–599. [Google Scholar] [CrossRef]
- Soria-Castro, R.; Schcolnik-Cabrera, A.; Rodríguez-López, G.; Campillo-Navarro, M.; Puebla-Osorio, N.; Estrada-Parra, S.; Estrada-García, I.; Chacón-Salinas, R.; Chávez-Blanco, A.D. Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells. J. Immunol. Res. 2019, 2019, 9678098. [Google Scholar] [CrossRef] [Green Version]
- Singh, D.; Gupta, S.; Singh, I.; Morsy, M.A.; Nair, A.B.; Ahmed, A.S.F. Hidden pharmacological activities of valproic acid: A new insight. Biomed. Pharmacother. 2021, 142, 112021. [Google Scholar] [CrossRef]
- Chateauvieux, S.; Eifes, S.; Morceau, F.; Grigorakaki, C.; Schnekenburger, M.; Henry, E.; Dicato, M.; Diederich, M. Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochem. Pharmacol. 2011, 81, 498–509. [Google Scholar] [CrossRef]
- Hansen, J.M.; Lucas, S.M.; Ramos, C.D.; Green, E.J.; Nuttall, D.J.; Clark, D.S.; Marchant, E.D.; Hancock, C.R.; Piorczynski, T.B. Valproic acid promotes SOD2 acetylation: A potential mechanism of valproic acid-induced oxidative stress in developing systems. Free Radic. Res. 2021, 1, 1130–1144. [Google Scholar] [CrossRef]
- Cai, Z.; Lim, D.; Liu, G.; Chen, C.; Jin, L.; Duan, W.; Ding, C.; Sun, Q.; Peng, J.; Dong, C.; et al. Valproic Acid-Like Compounds Enhance and Prolong the Radiotherapy Effect on Breast Cancer by Activating and Maintaining Anti-Tumor Immune Function. Front. Immunol. 2021, 12. [Google Scholar] [CrossRef]
- Gurvich, N.; Tsygankova, O.M.; Meinkoth, J.L.; Klein, P.S. Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation. Cancer Res. 2004, 64, 1079–1086. [Google Scholar] [CrossRef] [Green Version]
- Das Gupta, K.; Shakespear, M.R.; Iyer, A.; Fairlie, D.P.; Sweet, M.J. Histone deacetylases in monocyte/macrophage development, activation and metabolism: Refining HDAC targets for inflammatory and infectious diseases. Clin. Transl. Immunol. 2016, 5, e62. [Google Scholar] [CrossRef] [Green Version]
- Hamaidia, M.; Staumont, B.; Duysinx, B.; Louis, R.; Willems, L. Improvement of Malignant Pleural Mesothelioma Immunotherapy by Epigenetic Modulators. Curr. Top. Med. Chem. 2016, 16, 777–787. [Google Scholar] [CrossRef]
- Van den Bossche, J.; Neele, A.E.; Hoeksema, M.A.; De Winther, M.P.J. Macrophage polarization: The epigenetic point of view. Curr. Opin. Lipidol. 2014, 25, 367–373. [Google Scholar] [CrossRef]
- Saeed, S.; Quintin, J.; Kerstens, H.H.D.; Rao, N.A.; Aghajanirefah, A.; Matarese, F.; Cheng, S.C.; Ratter, J.; Berentsem, K.; Van Der Ent, M.A.; et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 2014, 345, 1251086. [Google Scholar] [CrossRef] [Green Version]
- Blondy, T.; D’Almeida, S.M.; Briolay, T.; Tabiasco, J.; Meiller, C.; Chéné, A.L.; Cellerin, L.; Deshayes, S.; Delneste, Y.; Fonteneau, J.F.; et al. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma. J. Immunother. Cancer 2020, 8, e000182. [Google Scholar] [CrossRef]
- Musson, R.A. Human Serum Induces Maturation of Human Monocytes in Vitro. Changes in Cytolytic Activity, Intracellular Lysosomal Enzymes, and Nonspecific Esterase Activity. Am. J. Pathol. 1983, 111, 331–340. [Google Scholar]
- Uchida, A.; Yanagawa, E. Natural cytotoxicity of human blood monocytes: Production of monocyte cytotoxic factors (MCF) during interaction with tumor cells. Immunol. Lett. 1984, 8, 311–316. [Google Scholar] [CrossRef]
- Webb, D.S.A.; Gerrard, T.L. IFN-alpha and IFN-gamma can affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity. J. Immunol. 1990, 144, 3643–3648. [Google Scholar]
- Te Velde, A.A.; Figdor, C.G. Monocyte mediated cytotoxic activity against melanoma. Melanoma Res. 1992, 1, 303–339. [Google Scholar] [CrossRef]
- Elavazhagan, S.; Fatehchand, K.; Santhanam, V.; Fang, H.; Ren, L.; Gautam, S.; Reader, B.; Mo, X.; Cheney, C.; Briercheck, E.; et al. Granzyme B Expression Is Enhanced in Human Monocytes by TLR8 Agonists and Contributes to Antibody-Dependent Cellular Cytotoxicity. J. Immunol. 2015, 194, 2786–2795. [Google Scholar] [CrossRef] [Green Version]
- Stelzer, E.H.K. Light-sheet fluorescence microscopy for quantitative biology. Nat. Methods 2014, 12, 23–26. [Google Scholar] [CrossRef]
- Van Lent, J.; Breukers, J.; Ven, K.; Ampofo, L.; Horta, S.; Pollet, F.; Imbrechts, M.; Geukens, N.; Vanhoorelbeke, K.; Declerck, P.; et al. Miniaturized single-cell technologies for monoclonal antibody discovery. Lab Chip 2021, 21, 3627–3654. [Google Scholar] [CrossRef]
- Villani, A.C.; Satija, R.; Reynolds, G.; Sarkizova, S.; Shekhar, K.; Fletcher, J.; Griesbeck, M.; Butler, A.; Zheng, S.; Lazo, S.; et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 2017, 356, eaah4573. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chee, S.J.; Lopez, M.; Mellows, T.; Gankande, S.; Moutasim, K.A.; Harris, S.; Clarke, J.; Vijayanand, P.; Thomas, G.J.; Ottensmeier, C.H. Evaluating the effect of immune cells on the outcome of patients with mesothelioma. Br. J. Cancer 2017, 117, 1341–1348. [Google Scholar] [CrossRef] [PubMed]
- Salaroglio, I.C.; Kopecka, J.; Napoli, F.; Pradotto, M.; Maletta, F.; Costardi, L.; Gagliosso, M.; Milosevic, V.; Ananthanarayanan, P.; Bironzo, P.; et al. Potential Diagnostic and Pronostic Role of Microenvironment in Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2019, 14, 1458–1471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Izzi, V.; Chiurchiu, V.; D’Aquilio, F.; Palumbo, C.; Tresoldi, I.; Modesti, A.; Baldini, P.M. Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. Int. J. Oncol. 2009, 34, 543–550. [Google Scholar] [CrossRef] [Green Version]
- Veltman, J.D.; Lambers, M.E.H.; van Nimwegen, M.; Hendriks, R.W.; Hoogsteden, H.C.; Hegmans, J.P.J.J.; Aerts, J.G. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br. J. Cancer 2010, 103, 629–641. [Google Scholar] [CrossRef] [Green Version]
- Dammeijer, F.; Lievense, L.A.; Kaijen-Lambers, M.E.; Van Nimwegen, M.; Bezemer, K.; Hegmans, J.P.; van Hall, T.; Hendriks, R.W.; Aerts, J.G. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy. Cancer Immunol. Res. 2017, 5, 535–546. [Google Scholar] [CrossRef] [Green Version]
- Ries, C.H.; Cannarile, M.A.; Hoves, S.; Benz, J.; Wartha, K.; Runza, V.; Rey-Giraud, F.; Pradel, L.P.; Feuerhake, F.; Klaman, I.; et al. Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell 2014, 25, 846–859. [Google Scholar] [CrossRef] [Green Version]
- Miselis, N.R.; Wu, Z.J.; Van Rooijen, N.; Kane, A.B.; Van Rooijen, N.; Kane, A.B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol. Cancer Ther. 2008, 7, 788–799. [Google Scholar] [CrossRef] [Green Version]
- Krug, L.M.; Kindler, H.L.; Calvert, H.; Manegold, C.; Tsao, A.S.; Fennell, D.; Öhman, R.; Plummer, R.; Eberhardt, W.E.E.; Fukuoka, K.; et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015, 16, 447–456. [Google Scholar] [CrossRef]
- Disselhorst, M.J.; Baas, P. Chemotherapy options versus “novel” therapies: How should we treat patients with malignant pleural mesothelioma. Transl. Lung Cancer Res. 2020, 9, S77–S85. [Google Scholar] [CrossRef]
- Staumont, B.; Jamakhani, M.; Costa, C.; Vandermeers, F.; Sriramareddy, S.N.; Redouté, G.; Mascaux, C.; Delvenne, P.; Hubert, P.; Safari, R.; et al. TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma. Cancers 2020, 12, 1484. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hoyos, C.; Fontaine, A.; Jacques, J.-R.; Heinen, V.; Louis, R.; Duysinx, B.; Scherpereel, A.; Wasielewski, E.; Jamakhani, M.; Hamaidia, M.; et al. HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells. Cancers 2022, 14, 2164. https://doi.org/10.3390/cancers14092164
Hoyos C, Fontaine A, Jacques J-R, Heinen V, Louis R, Duysinx B, Scherpereel A, Wasielewski E, Jamakhani M, Hamaidia M, et al. HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells. Cancers. 2022; 14(9):2164. https://doi.org/10.3390/cancers14092164
Chicago/Turabian StyleHoyos, Clotilde, Alexis Fontaine, Jean-Rock Jacques, Vincent Heinen, Renaud Louis, Bernard Duysinx, Arnaud Scherpereel, Eric Wasielewski, Majeed Jamakhani, Malik Hamaidia, and et al. 2022. "HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells" Cancers 14, no. 9: 2164. https://doi.org/10.3390/cancers14092164